News - Vyvanse, Neurological


Current filters:


Popular Filters

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD


Ireland-headquartered drugmaker Shire says it has agreed to a written request by the US Food and Drug…


Shire will drop MDD indication for Vyvanse after failed endpoints in Ph III


Shares of Ireland-headquartered Shire fell 2.4% to £30.67 in early trading, after the company presented…


Added benefit of lisdexamfetamine not proven, says German watchdog


Ireland-headquartered Shire's (LSE: SHP) Elvanse (lisdexamfetamine dimesylate) demonstrated no added…

ElvanseEuropelisdexamfetamine dimesylateNeurologicalPharmaceuticalPricingRegulationShireVyvanse

US FDA adds new indication for Shire's ADHD drug Vyvanse; 1st-qtr results


Ireland-headquartered Shire (LSE: SHP) says that the US Food and Drug Administration has approved its…

FinancialNeurologicalNorth AmericaPharmaceuticalRegulationShireVyvanse

Shire agrees to settlement with US government over ADHD drug marketing


Ireland-headquartered drugmaker Shire (LSE: SHP) said on Friday that it has reached an agreement in principle…

Adderall XRDaytranaFinancialLegalNeurologicalNorth AmericaPharmaceuticalShireVyvanse

Positive response from European regulatory procedure supports Shire's Elvanse for ADHD


Ireland headquartered Shire (LSE: SHP) yesterday announced a positive outcome from the European Decentralized…

ElvanseEuropelisdexamfetamine dimesylateNeurologicalPharmaceuticalRegulationShireTyvenseVyvanse

FDA accepts Shire's sNDA for Vyvanse as maintenance treatment


Ireland-headquartered drugmaker Shire (LSE: SHP) that the US Food and Drug Administration has accepted…

NeurologicalNorth AmericaPharmaceuticalRegulationShireVyvanse

Efficacy of Shire's Vyvanse maintained in ADHD adolescents after at least six months


A significantly lower proportion of subjects experiencing treatment failure whilst receiving UK specialty…


Shire forecasts strong 2012 EPS growth on record 2011 sales; Vyvanse news


Shire (LSE: SHP), the UK’s third-largest drugmaker, posted a pleasing set of financial for full-year…

FinancialNeurologicalNorth AmericaPharmaceuticalRegulationShireVyvanse

Global ADHD market set to grow at a CAGR of 8% to 2018


The global attention deficit hyperactivity disorder (ADHD) therapeutics market was valued at $3.86 billion…

DaytranaGlobalIntunivMarkets & MarketingNeurologicalPharmaceuticalShireVyvanse

Back to top